# Onepot AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onepot-ai

- Industry: Software
- Headquarters: South San Francisco, US
- Website: www.onepot.ai
- Latest round: Seed (Nov 19, 2025)
- Investors on record: 3

## About

Based in the US, Onepot AI offers an innovative platform for AI-enabled small molecule synthesis, ensuring secure data handling and optimized molecular design crucial for pharmaceutical research.Onepot AI, founded in 2025, is based in South San Francisco, US. The company specializes in AI-driven small molecule synthesis and has completed 2 deals. The founder's history is not specified, and there are no mentions of significant pivots or changes in strategy.Onepot specializes in AI-enabled small molecule synthesis, offering a robust platform that encrypts molecular structures end-to-end for secure data handling. The core product leverages advanced algorithms to optimize the design and synthesis of small molecules, which are essential in pharmaceutical research and development. This service is particularly relevant for researchers and companies focused on drug discovery, as it allows for the rapid and secure generation of molecular candidates. Onepot's solutions cater primarily to the pharmaceutical and biotechnology sectors, targeting clients engaged in developing new therapeutics, with a focus on markets in North America, Europe, and Asia. By providing a secure and efficient synthesis platform, Onepot addresses the critical need for confidentiality and speed in the increasingly competitive landscape of drug development.Onepot generates revenue through a subscription-based model that provides access to its synthesis platform. Clients, primarily from the pharmaceutical and biotech industries, engage with the company on an ongoing basis, paying for various tiers of service that may include additional features such as advanced analytics and increased synthesis capacity. The pricing structure accommodates a range of client needs, from small research teams to large pharmaceutical corporations, ensuring flexibility in how clients can access and utilize Onepot’s offerings. Transactions are typically structured as direct business-to-business engagements, where clients may enter into annual contracts or project-based agreements based on their specific molecular synthesis requirements. The flagship service emphasizes security and efficiency, appealing to a client base that prioritizes the confidentiality of their proprietary research.Onepot AI raised an undisclosed amount of pre-seed funding, which was part of a larger USD 13 mn pre-seed and Seed funding round. The company plans to utilize this funding to build a second lab in San Francisco, expand its team, and enhance its compound discovery engine. This strategic investment aims to support upcoming product developments and bolster the company’s capacity in the pharmaceutical market.

## Funding rounds

- Seed, Nov 19, 2025 — Khosla Ventures, Speedinvest, Fifty Years

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed
- Speedinvest (https://capitalatlas.ai/funds/speedinvest) — Seed
- Fifty Years (https://capitalatlas.ai/funds/fifty-years) — Seed